The stress‐activated kinases c‐Jun N‐terminal kinase (JNK) and the mitogen‐activated protein kinase (MAPK) p38 play a key role in response to stress insults (Arimoto et al, 2008; Wu et al, 2020), and we therefore explored whether elevated ROS upon FGFR/PLK1 inhibition can activate JNK and p38 in KRAS‐mutant cancer cells. The gene discussed is KRAS; the disease is cancer.